Oral levosimendan in ALS: The REFALS phase 3 study design

Authors
Category Primary study
ConferenceAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Year 2018
This article has no abstract
Epistemonikos ID: 99e5b270e751f1cf4b3bfed3ffdafa6b2ced0221
First added on: Apr 29, 2026